Optic nerve astrocyte reactivity protects function in experimental glaucoma and other nerve injuries

Daniel Sun, Sara Moore, and Tatjana C. Jakobs

Department of Ophthalmology, Massachusetts Eye and Ear Infirmary/Schepens Eye Research Institute, Harvard Medical School, Boston, MA 02114

Reactive remodeling of optic nerve head astrocytes is consistently observed in glaucoma and other optic nerve injuries. However, it is unknown whether this reactivity is beneficial or harmful for visual function. In this study, we used the Cre recombinase (Cre)–loxP system under regulation of the mouse glial fibrillary acidic protein promoter to knock out the transcription factor signal transducer and activator of transcription 3 (STAT3) from astrocytes and test the effect this has on reactive remodeling, ganglion cell survival, and visual function after experimental glaucoma and nerve crush. After injury, STAT3 knockout mice displayed attenuated astrocyte hypertrophy and reactive remodeling; astrocytes largely maintained their honeycomb organization and glial tubes. These changes were associated with increased loss of ganglion cells and visual function over a 30-day period. Thus, reactive astrocytes play a protective role, preserving visual function. STAT3 signaling is an important mediator of various aspects of the reactive phenotype within optic nerve astrocytes.

INTRODUCTION

Glaucoma is the second leading cause of blindness worldwide, affecting an estimated 70 million people (Quigley, 2011; Pascolini and Mariotti, 2012). It causes a progressive and irreversible loss of retinal ganglion cells, leading to visual loss and blindness. The exact molecular mechanisms involved in this damage are not yet fully elucidated (Nickells et al., 2012). An elevated intraocular pressure (IOP) is the most important risk factor in glaucoma, and current medications focus on lowering the IOP. However, this is not always effective, with many patients continuing to progress in the disease even after IOP lowering. As yet, there are no clinically approved neuroprotective treatments that directly target the pathogenic mechanisms in the retina or optic nerve; IOP-lowering treatments address a risk factor. An important step toward finding alternative treatments is to better understand the pathogenic mechanisms underlying glaucoma. This involves going beyond studying the ganglion cells themselves to understand the potential role that nonneuronal cell types have in supporting the ganglion cells, including glial cells such as astrocytes.

The optic nerve head is an important site for early glaucomatous damage; there are profound alterations in tissue composition and architecture, disruptions in axonal transport, and critical axonal insult (Minckler et al., 1977; Johnson et al., 1996; Pease et al., 2000; Burgoyne et al., 2004; Jakobs et al., 2005; Balaratnasingam et al., 2007; Howell et al., 2007; Buckingham et al., 2008; Soto et al., 2008; Chidlow et al., 2011). Furthermore, the characteristic pattern of ganglion cell loss in glaucomatous retinas is best explained by a requirement for damage to axon bundles in the optic nerve head (Schlamp et al., 2006; Howell et al., 2007). Ganglion cell axons exit the eye through a scleral opening that contains, depending on the species, a lamina cribrosa or a glial lamina. In humans, the lamina cribrosa is formed by a series of collagenous sieve-like plates through which bundles of ganglion cell axons pass. The surface of the plates and the pores are covered by a dense network of astrocytes (Hernandez et al., 2008). In the glial lamina of mice and rats, there is very little collagen, and instead, the axon bundles pass through pores that are formed by a dense network of astrocytes; hence, this arrangement has been termed the glial lamina (May and Lütjen-Drecoll, 2002; Howell et al., 2007; Sun et al., 2009). In either case, the lamina region is densely populated with astrocytes.

In a normal state, astrocytes support the axons they ensheath, but in response to injury/disease, they remodel and become reactive, inducing changes in morphology, gene expression, and function that have the potential for both beneficial and detrimental effects (Sofroniew and Vinters, 2010). Some of these reactive changes may include hypertrophy, proliferation, migration, release of extracellular matrix, up-regulation of complement and intermediate filaments (e.g., glial fibrillary acidic protein [GFAP], vimentin, and nestin), and scar formation (Hernandez, 2000; Sun et al., 2010; Sun and Jakobs, 2012; Lye-Barthel et al., 2013). Reactive remodeling is consistently observed in human and animal models of glaucoma (Morrison et al., 1990; Quigley et al., 1991; Hernandez and Ye, 1993; Johnson et al., 2007; Hernandez et al., 2008; Burgoyne, 2011). A long-standing question in glaucoma research is whether reactive astro-
cytes in the lamina region are harmful or beneficial for visual outcome. Although most agree that astrocytes do play an important role, current data fall short of demonstrating what this role is, and the function and mechanism of reactivity have not been studied.

STAT3 is a critical regulator of astrocyte reactivity and glial scar formation in both the brain and spinal cord (Herrmann et al., 2008; Wanner et al., 2013; Zhang et al., 2013; O’Callaghan et al., 2014; Ben Haim et al., 2015; Wong et al., 2015). STAT3 is a member of the Jak–STAT signaling family and is activated by phosphorylation through several cytokines and growth factors implicated in the injury response, including IL-6, ciliary neurotrophic factor, leukemia inhibitory factor, epidermal growth factor, and transforming growth factor α (Balasingam et al., 1994; Winter et al., 1995; Klein et al., 1997; Rabchevsky et al., 1998; Levison et al., 2000; Aaronson and Horvath, 2002). Astrocytes in the optic nerve, brain, and spinal cord all express STAT3, and its activation increases markedly after injuries and diseases such as trauma, ischemia, inflammation, neurodegenerative diseases, and in a rat model of transient elevation in IOP (Cattaneo et al., 1999; Acarin et al., 2000; Justicia et al., 2000; Sriram et al., 2004; Yamauchi et al., 2006; Zhang et al., 2013; Ben-Haim et al., 2015). In the injured brain and spinal cord, conditional KO (CKO) of STAT3 or its extracellular receptor gp130 from astrocytes attenuated the injury-induced reactive phenotype, minimizing cellular hypertrophy, GFAP up-regulation, and scar formation (Okada et al., 2006; Drögemüller et al., 2008; Herrmann et al., 2008; Haroon et al., 2011; Wanner et al., 2013).

Using the same transgenic strategy as in the brain and spinal cord, we aimed to determine whether attenuating astrocyte reactivity in the optic nerve head after experimental glaucoma improves or worsens ganglion cell survival and visual function. We used the Cre recombinase (Cre)–loxP system under regulation of the mouse GFAP promoter to conditionally knock out STAT3 from astrocytes and test the effect this has on astrocyte reactivity, ganglion cell survival, and visual function after transient ocular hypertension (OHT), chronic OHT, and an optic nerve crush. The transient OHT model represents a subtle mild injury that mimics the early stages of glaucoma (Crowston et al., 2015). Chronic OHT was induced via a microbead injection and gives a sustained chronic elevation in IOP (Sappington et al., 2015). STAT3 is a member of the Jak–STAT signaling family and is activated by phosphorylation through several cytokines and growth factors implicated in the injury response, including IL-6, ciliary neurotrophic factor, leukemia inhibitory factor, epidermal growth factor, and transforming growth factor α (Balasingam et al., 1994; Winter et al., 1995; Klein et al., 1997; Rabchevsky et al., 1998; Levison et al., 2000; Aaronson and Horvath, 2002). Astrocytes in the optic nerve, brain, and spinal cord all express STAT3, and its activation increases markedly after injuries and diseases such as trauma, ischemia, inflammation, neurodegenerative diseases, and in a rat model of transient elevation in IOP (Cattaneo et al., 1999; Acarin et al., 2000; Justicia et al., 2000; Sriram et al., 2004; Yamauchi et al., 2006; Zhang et al., 2013; Ben-Haim et al., 2015). In the injured brain and spinal cord, conditional KO (CKO) of STAT3 or its extracellular receptor gp130 from astrocytes attenuated the injury-induced reactive phenotype, minimizing cellular hypertrophy, GFAP up-regulation, and scar formation (Okada et al., 2006; Drögemüller et al., 2008; Herrmann et al., 2008; Haroon et al., 2011; Wanner et al., 2013).

RESULTS
The normal appearance and visual function of GFAP–STAT3–CKO mice

The glial lamina of GFAP–STAT3–CKO mice was indistinguishable from GFAP–STAT3–Cre+ (control strain) and C57BL/6 mice (Fig. 1, A–I). In all three mouse strains, a transverse cross section of this region showed astrocyte processes labeled with GFAP forming glial tubes through which ganglion cell axons pass (Fig. 1, A–B, D–E, and G–H; red dashed ellipses show such glial tubes; Howell et al., 2007; Sun et al., 2009). Numerous thick primary processes bundle to form the walls of the glial tubes (Fig. 1 A′, arrowheads), and thinner processes run into the center of the tubes (Fig. 1 A′, arrows). This arrangement gives the glial lamina an overall honeycomb appearance, with the center of the glial tubes having more process-free area. Ultrastructural examination of the GFAP–STAT3–CKO glial lamina showed that axonal morphology and organization was similar to the other two strains; all have similar-sized axons and a normal complement of microtubules and neurofilaments (Fig. 1, C, C′, F′F′, I, and I′). Several other histological and functional features of the three mouse strains were compared, and they were all indistinguishable from each other. These included: the IOPs, the number of ganglion cells, the spatial frequency threshold, and the electroretinogram (ERG) response (Fig. S1).

As a preliminary measure, we sought to determine whether the IOP of STAT3 KO-transgenic mice would behave in a similar manner to C57BL/6 mice after microbead injection. After successful injections (Fig. S2 A), the pattern and duration of IOP elevation were the same in all three mouse strains and consistent with published results (Fig. S2 B; Chen et al., 2011; Della Santina et al., 2013; Gao and Jakobs, 2016). Furthermore, there was no statistical difference in the Δ cumulative IOP (ΔcIOP) or peak IOP reached, indicating that all animals received comparable pressure insult (see the Chronic OHT section of Materials and methods and Fig. S2 D).

Injury induces an early up-regulation of pSTAT3 in astrocytes of the glial lamina but not in retinal astrocytes

Untreated mice displayed immunohistochemically undetectable levels of pSTAT3 (Fig. 2, A–C). Injury induced an early up-regulation of pSTAT3 in many astrocytes, identified by their characteristic transversely elongated nuclei (Fig. 2, D–AA, arrows), which were enwrapped by GFAP-labeled processes (Fig. 2 E′, arrows). Moreover, pSTAT3 labeling was completely abolished in the GFAP–STAT3–CKO mice, further indicating that the up-regulation was exclusively in astrocytes (not depicted). Transient OHT induced an up-regulation of pSTAT3 at days 1 and 3, followed by a return to normal by day 7 (Fig. 2, D–K). Chronic OHT similarly induced an up-regulation at day 1, but this was maintained through to at least day 7 (Fig. 2, L–S). Optic nerve crush induced a different time course of STAT3 activation. Phosphorylated STAT3 was up-regulated as early as 4 h after crush and lasted only until day 3 (Fig. 2, T–AA).
ina and whether STAT3 was activated in retinal astrocytes and Müller cells. We focused our analysis on mice subjected to chronic OHT and at days 1 and 3 after injury, a time when there was discernible up-regulation of pSTAT3 within the glial lamina. As expected from a previous study (Zhang et al., 2013), chronic OHT did not alter STAT3 immunoreactivity in any of the mouse strains, including the GFAP-STAT3-CKO strain at 1 or 3 d after injury (data depicted only for day 3; Fig. 3, A–D). Injury induced low-level up-regulation of pSTAT3 in many retinal cell types (chronic OHT: Fig. 3, F–H and J–L; optic nerve crush: Fig. 3, M–O). However, we were surprised to find that, after chronic OHT, there were undetectable levels in astrocytes of GFAP-STAT3-Cre− and C57BL/6 retinas (data depicted only for day 3; Fig. 3, F and G), despite the discernible up-regulation within astrocytes of the glial lamina at these time points. Furthermore, these retinal astrocytes were not significantly reactive (Fig. 3, E–H). As expected, there was no pSTAT3 labeling in astrocytes of GFAP-STAT3-CKO retinas (Fig. 3 H). In contrast to the astrocytes, Müller cells in all mouse strains showed an up-regulation of pSTAT3 (Fig. 3, J–L) and were reactive, as some of their processes

Figure 1. Untreated GFAP-STAT3-CKO mice have a glial lamina that appeared similar to its control strain and C57BL/6 mice. (A–B, D–E, and G–H) Transverse cross sections of optic nerves from the different mouse strains labeled for GFAP alone (A, A', D, D', G, and G') or colocalized with SMI32 (B, E, and H). (A, inset) The red bar in the schematic of the optic nerve head indicates where the transverse sections have been made. Arrows indicate the thin processes of astrocytes, arrowheads indicate the thick main processes, and the dashed ellipses indicate glial tubes. (C, C', F, F', I, and I') Ultrastructural examination of the optic nerve showing the axon–astrocyte organization and their morphology. Each panel represents a typical finding from a sample of three to five mice. Bars: (A, D, and G) 50 µm; (A', B, D', E, G', and H) 20 µm; (C, F, and I) 2 µm.
became immunoreactive for GFAP (Fig. 3, F–H). Interestingly, severe injuries such as an optic nerve crush induced distinct pSTAT3 up-regulation within astrocytes in both the GFAP-STAT3-Cre$^+$ and C57BL/6 mice but not in the GFAP-STAT3-CKO mice (Fig. 3, M–O).

Attenuated astrocyte reactivity and remodeling in GFAP-STAT3-CKO glial lamina

Next, we determined the effect that knocking out STAT3 has on astrocyte reactivity within the glial lamina by examining GFAP immunoreactivity. We assessed the reorganization of...
and determined that the reorganization was most prominent at day 3 after injury (Sun et al., 2010, 2013). We and others have previously shown that GFAP mRNA levels within astrocyte processes and process hypertrophy at day 3 after injury. This time was chosen as we previously performed a time series analysis of GFAP immunostaining (at days 1, 3, and 7) and determined that the reorganization was most prominent at day 3 after injury (Sun et al., 2010, 2013). We and others have previously shown that GFAP mRNA levels within

Figure 3. Immunostaining of STAT3 within the optic nerve head and pSTAT3 within the retina. (A–D) Transverse cross sections of the glial lamina from normal C57BL/6 mice and those that underwent chronic OHT immunostained for STAT3. (E–H) Vertical sections of the retina immunostained for either GFAP alone or for GFAP (green) and pSTAT3 (red). Arrows show the GFAP-labeled processes of mildly reactive Müller cells. Arrowheads show the cell bodies of GFAP-labeled astrocytes. (I–L) Vertical sections of the retina immunostained for either glutamine synthetase (GS) alone or for glutamine synthetase (green) and pSTAT3 (red). Arrows show colocalization of glutamine synthetase–labeled Müller cells with pSTAT3. (M–O) Vertical sections of the retina immunostained for GFAP (green) and pSTAT3 (red). Arrows show the cell bodies of GFAP-labeled astrocytes. For all the images, we observed a similar labeling pattern at day 1 (not depicted). GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer. Each panel represents a typical finding from a sample of three to five mice. Bars: (A–D) 10 µm; (E–L) 25 µm; (M–O) 25 µm.
the optic nerve head do not change significantly after injury, even after severe injuries such as a nerve crush (Johnson et al., 2007; Qu and Jakobs, 2013; Sun et al., 2013; Choi et al., 2015).

Each of the three injuries induced significant reactive remodeling of astrocytes in the GFAP-STAT3-Cre− and C57BL/6 glial lamina. There was a loss of the large distinct glial tubes and the overall honeycomb arrangement (Fig. 4, A and C–H). However, this remodeling was attenuated in the GFAP-STAT3-CKO mice, where large distinct glial tubes remained and the overall honeycomb arrangement was largely intact (Fig. 4, I–K; dashed ellipses show the glial tubes). Quantification of the remodeling (flooding algorithm; see the Image collection and analysis section of Materials and methods) demonstrated that GFAP-STAT3-CKO mice have 20–30% more process-free area (or black space) compared with the other two mouse strains and across the three injuries, indicating the astrocytes undergo less remodeling (Fig. 4 B and Table S1).

Next, we examined the hypertrophy of astrocyte processes by measuring the width of the thickest GFAP-labeled process at a location of 12–15 µm away from DAPI-labeled nuclei (Sun et al., 2010). Processes in the glial lamina of GFAP-STAT3-Cre− and C57BL/6 mice exhibited significant hypertrophy, showing a 1.5–1.7-times increase in thickness across the three different injury models. This reactive hypertrophy was significantly attenuated in the GFAP-STAT3-CKO mice, the processes displaying a 1.1–1.2-times increase in thickness (Fig. 4 L and Table S1).

**Attenuated reactive remodeling in the GFAP-STAT3-CKO glial lamina was associated with greater ganglion cell loss**

Next, we wanted to determine whether the diminished astrocyte reactivity within the glial lamina of GFAP-STAT3-CKO mice affected ganglion cell survival. We counted cells in whole mounted retinas that were immunostained with both βIII-tubulin, a ganglion cell–specific marker (Chen et al., 2011; Gao and Jakobs, 2016), and DAPI. Counts were performed at a single time point after injury, the earliest time at which we knew from previous studies there would be sufficient ganglion cell loss to see an effect from the STAT3 KO. Ganglion cells degenerate rapidly after an optic nerve crush (within 3–7 d depending on the duration of the crush; Li et al., 1999; McKinnon et al., 2009; Ryu et al., 2012; Liu et al., 2014; Choudhury et al., 2015), and we chose to perform our counts at day 3 after crush. In contrast, ganglion cell degeneration in the chronic OHT model is much slower, and we counted cells at day 30, a time point also used by numerous other studies (Sappington et al., 2010; Chen et al., 2011; Della Santina et al., 2013; Gao and Jakobs, 2016). For the transient OHT model, we chose an endpoint time of 14 d based on our previous study (Sun et al., 2013). GFAP-STAT3-CKO mice showed a preferential loss of ganglion cells after each of the injuries, losing 20–30% more ganglion cells compared with their control strain and C57BL/6 mice (Fig. 5 A and Table S2).

We confirmed ganglion cell loss by counting surviving axons from paraphenylenediamine (PPD)-stained cross sections of the optic nerves (see the Electron microscopy and quantification of axon loss with PPD stain section of Materials and methods). PPD darkly stains damaged axons allowing for sensitive detection of injury (Fig. 5, B and C, arrows). We found that, at day 14 after transient OHT, GFAP-STAT3-CKO mice showed a significantly greater amount of ganglion cell loss compared with axon loss (P < 0.01; Student’s t test; Fig. 5, A and D; and Table S2). However, there was no significant difference when we made this comparison with the other two mouse strains. At day 30 after chronic OHT, there was no significant difference between ganglion cell loss and axon loss for any of the mouse strains (P > 0.1; Student’s t test; Fig. 5, A and F; and Table S2). Our counts here were performed late after the onset of injury, and we cannot speak to whether there was an early preferential loss of axons compared with ganglion cell soma, as has been shown to occur in glaucomatous neurodegeneration (Howell et al., 2007). We also noted that there was no difference in the cross-sectional area of the optic nerve for any of the mouse strains after both transient and chronic OHT (Fig. 5, E and G). Because of the severe nature of an optic nerve crush injury, we did not examine the nerves with PPD.

**Attenuated reactive remodeling in the GFAP-STAT3-CKO glial lamina was associated with greater visual function loss**

To evaluate the effect of knocking out STAT3 on visual function after injury, we assessed the full-field dark–adapted ERG and the optomotor response. Ganglion cell function was assessed by measuring the positive scotopic threshold response (STR, [pSTR]), a component of the ERG most sensitive to IOP elevations in both mice and rats (Fortune et al., 2004; Bui et al., 2005; He et al., 2006; Holcombe et al., 2008; Kong et al., 2009; Frankfort et al., 2013; Pérez de Lara et al., 2014; Porciatti, 2015). Consistent with the greater ganglion cell loss, GFAP-STAT3-CKO mice showed the greatest reduction in pSTR amplitude across the different injuries (Figs. 6 and 7). By day 30, these mice showed a 20–30% greater reduction in amplitude compared with the other two strains (Fig. 7 D). There was no significant difference in the reduction in pSTR amplitude between GFAP-STAT3-Cre− and C57BL/6 mice for any of the injuries or times. Outer retinal function was assessed using the scotopic a- and b-wave amplitude. As expected, both waveforms were not as affected by injury as the inner retina–derived pSTR. Although injury induced a small decrease in the a- and b-wave amplitude over time, there was no significant difference in this decrease between the mouse strains for each of the injuries (Fig. 8).

Similar to their ERG response, GFAP-STAT3-CKO mice demonstrated a preferential reduction in spatial frequency thresholds that was most evident after chronic OHT (Fig. 9). The treated right eye of GFAP-STAT3-CKO mice showed a significantly greater reduction than the right eye of its control strain from day 3 onwards (Fig. 9 A). By day
Figure 4. STAT3 KO mice show attenuated astrocyte reactivity and remodeling after injury.

(A) A transverse section of the glial lamina from normal C57BL/6 mice immunostained for GFAP. (B) Changes in the amount of GFAP immunonegative space within the glial lamina across the various mouse strains and injury models. (C–K) Transverse sections of the glial lamina immunostained for GFAP. (L) A comparison of the change in the thickness of GFAP-labeled processes within the glial lamina across the various mouse strains and injury models. (B and L) See Table S1 for the absolute numbers. Also, we are not making comparisons across injury models but, rather, between strains within each injury model. In all cases, there were no statistical differences between GFAP-STAT3-Cre− and C57BL/6 mice. Each gray dot represents an individual mouse (n = 6 for each group), and for each mouse in L, processes from 10–15 astrocytes were averaged. Horizontal lines represent the group means and SD. One-way ANOVA with Tukey posttest was used. *, P < 0.05; **, P < 0.01. (A and C–K) Each image represents a typical finding from a sample of six mice. The dashed ellipses indicate the distinct glial tubes. Bar, 20 μm.
30, thresholds were reduced to $0.16 \pm 0.03$ cycles/degree compared with $0.32 \pm 0.03$ cycles/degree in the control strain ($P < 0.001$). Thresholds were not as greatly reduced after transient OHT (Fig. 9 B), where a significant difference was first observed at day 14 and thresholds were reduced to $0.31 \pm 0.05$ cycles/degree. Because of the severe nature of a nerve crush, optomotor responses were completely abolished in the treated right eye of all the mouse strains from as early as day 3 after crush (Fig. 9 C). Thresholds were affected neither in the untreated left eyes of any mouse strain nor after any of the injuries.

**DISCUSSION**

Although it is well accepted that optic nerve head astrocytes undergo significant reactive remodeling in glaucoma, its mechanism, function, and effect on visual function are not...
well studied. Is it a beneficial or harmful response for visual outcome? Here, we report that the STAT3 signaling pathway is an important mediator of astrocyte reactivity in the glaucomatous optic nerve head, playing an important role in astrocyte hypertrophy and in the formation of a glial scar. Astrocyte reactivity is beneficial, as attenuating reactivity in injured mice leads to increased ganglion cell and visual function loss.

**Chronic OHT induces reactive changes in the glial lamina more than the retina**

In GFAP-STAT3-Cre− and C57BL/6 mice subjected to chronic OHT, pSTAT3 was up-regulated early in reactive astrocytes within the glial lamina (days 1 and 3). Retinal astrocytes at this time did not show an up-regulation of pSTAT3 and were not highly reactive. Therefore, the KO of STAT3 would have little effect on retinal astrocytes. In contrast, Müller cells showed a low-level up-regulation of pSTAT3 and some reactivity; we observed a few processes with increased GFAP immunoreactivity. These findings suggest that chronic OHT induces distinct reactive changes primarily in the glial lamina. The deleterious effects on visual function that we observed in the STAT3 KO animals are therefore likely caused by the inhibition of astrocyte reactivity in the glial lamina rather than the retina.

**STAT3 signaling and its role in reactive astrocytes**

STAT3 is involved in many cellular processes, not only with those directly related to the classical reactive phenotype such as structural remodeling, proliferation, and migration, but also with processes hypothesized to be important for the pathophysiology of glaucoma, such as inflammation and deprivation of growth factors.

For example, inhibiting or knocking out STAT3 attenuated the increase in GFAP mRNA and/or protein levels in reactive astrocytes. Levels of GFAP are also reduced by STAT3 inhibition in untreated animals, suggesting that STAT3 controls the basal expression of GFAP (Herrmann et al., 2008; Wanner et al., 2013; Levine et al., 2016). Evidence for the involvement of STAT3 in astrocyte proliferation is indirect. JAK inhibitors reduce the number of proliferating reactive astrocytes after spinal cord injury (Tsuda et al., 2011), and the formation of the glial scar, which is composed of newly proliferated astrocytes, is also altered in STAT3 KO mice (Wanner et al., 2013; Anderson et al., 2016). STAT3 KO reduces the
migration of reactive astrocytes after in vitro scratch injury (Okada et al., 2006), and STAT3 regulates the transcription of genes implicated in matrix remodeling and cell adhesion proteins (Gao and Bromberg, 2006). During glial scar formation, reactive astrocyte processes reorient themselves to enclose immune cells and fibroblasts. This organization is disrupted in STAT3 KO mice (Wanner et al., 2013).

With regards to inflammation, STAT3 in astrocytes regulates the production of cytokines and chemokines during reactivity. Inhibition of the STAT3 pathway in astrocytes reduced mRNA levels of IL-6, IL1β, IL-4, and vascular endothelial growth factor (Wang et al., 2012b). Intrathecal injection of the STAT3 inhibitor Stat6 in an LPS model of inflammation reduced the astrocytic expression of Ccl20, Cx3cl1, Cxcl5, and Cxcl10 (Liu et al., 2013). Lipocalin 2, a protein highly expressed by reactive astrocytes (Zamanian et al., 2012), may serve as an inflammatory mediator, and its production by reactive astrocytes is dependent on STAT3 (Shioritori-Hayashi et al., 2015). Factors released by reactive astrocytes in a STAT3-dependent manner may also affect microglial reactivity and modulate their activity (Nobuta et al., 2012; Ben Haim et al., 2015; Hristova et al., 2016).

We report in this study that inhibiting astrocyte reactivity led to a greater loss of ganglion cells and visual function. The most parsimonious explanation—and the one we favor—would be that astrocyte reactivity is protective of ganglion cell axons, and therefore, interfering with the reactive process leads to a more severe phenotype. However, our results should be interpreted with caution. First, we cannot exclude the possibility that knocking out STAT3 also affects constitutive pathways unrelated to reactivity, causing the beneficial phenotype we observed. Second, though STAT3 is a key regulator, multiple other pathways may also be associated with reactivity. NF-κB, endothelin-1, JNK/c-Jun, CEPB1, EphB2, Nrf2, and SOCS3 can also play a role in mediating various aspects of reactivity, including up-regulation of structural molecules, hypertrophy, proliferation, migration, scar formation, and anti-inflammatory effects (Sofroniew, 2009).

Figure 7. Changes in the pSTR amplitudes after injury. (A–D) A single-flash intensity of –5.00 log cd.s.m⁻² was used to measure pSTR. The actual percentage value for the pSTR amplitude at day 30 is tabulated in D, where values are mean ± SD. A two-way repeated-measures ANOVA with Bonferroni posttest for three selected comparisons was performed (GFAP-STAT3-CKO vs. GFAP-STAT3-Cre; GFAP-STAT3-CKO vs. C57BL/6, and GFAP-STAT3-Cre vs. C57BL/6). Here, we only show the statistical differences between the GFAP-STAT3-CKO mice and its control strain (GFAP-STAT3-Cre). There was no significant difference between GFAP-STAT3-Cre and C57BL/6 mice for any injury and for any times after injury. Changes in the pSTR amplitude were calculated from the same eye before and after injury (e.g., amplitude after injury/amplitude before injury × 100%). Each colored dot represents an individual mouse (n = 6 for each mouse strain in each injury model). *, P < 0.05; **, P < 0.01; ***, P < 0.001.
The fact that knocking out STAT3 did not completely prevent process hypertrophy and remodeling does indeed suggest that other pathways are involved.

**Transient episodes of pressure-related stress can induce long-term damage**

The transient OHT model helps us to understand processes that are relevant to the early stages of glaucoma because it mimics the cycles of relatively mild increases in pressure to which the optic nerve head is repeatedly exposed (Li and Liu, 2008; Downs et al., 2011; Crowston et al., 2015). An interesting finding from this study was that a single transient elevation of IOP to 30 mmHg for 2 h induced long-term histological and functional damage. In a previous study, we elevated the IOP to 30 mmHg for 1 h and did not observe gross degeneration of the axons, albeit axon or ganglion cell loss was not quantified and the ERG response was not examined (Sun et al., 2013). A study by Kong et al. (2009) examined the long-term effects of a single transient elevation of IOP on the ERG components and found a similar result to our current study. 7 d after a single elevation of the IOP to 50 mmHg for 30 min, there was a persistent reduction in the pSTR amplitude of 30%. Crowston et al. (2015) found a similar degree of functional degeneration, although in both these studies, ganglion cell loss was not assessed. He et al. (2006) suggested that the IOP integral (e.g., 50 mmHg × 30 min = 1,500) is an important predictor of retinal dysfunction, so it is not surprising that in our current study, which has an IOP integral of 3,600 (30 mmHg × 120 min), we saw persistent histological and functional deficits even at day 14 after injury. The capacity to recover after transient OHT depends on the magnitude and duration of the elevation, and both factors collectively define a threshold for permanent damage (He et al., 2006; Kong et al., 2009; Bui et al., 2013). It may be that by increasing the duration of the IOP elevation from 1 to 2 h a critical threshold at which full recovery is possible has been passed. These results suggest that a single episode of pressure-related stress can produce long-term damage; a chronic elevation in IOP may not be required to cause irreversible losses.

**Beneficial functions of reactive astrocytes**

Astrocytes respond to virtually all CNS injuries and diseases by becoming reactive. This is not a single all-or-none
response but a complex, heterogenous process controlled in a context-dependent manner by a multitude of signaling mechanisms. In line with this complexity, reactive astrocytes are attributed to have both beneficial and detrimental effects (Sofroniew and Vinters, 2010). In the brain and spinal cord, studies across various injury models (e.g., acute traumatic injury, stroke, inflammation, and neurodegenerative diseases) have largely concluded that the reactive process, at least in its early stages, is adaptive and beneficial—that various functions of reactive astrocytes are normal and indeed essential for the proper recovery of tissue.

Numerous in vivo transgenic loss-of-function studies provide evidence that gene deletion or KO of molecules, such as STAT3, from astrocytes or ablation of reactive astrocytes leads to increased lesion size, exacerbates the spread of and prolongs the inflammatory response, increases neuronal loss and demyelination, and eventually impairs functional recovery (Bush et al., 1999; Faulkner et al., 2004; Brambilla et al., 2005; Myer et al., 2006; Okada et al., 2006; Herrmann et al., 2008; Li et al., 2008; Voskuhl et al., 2009; Wanner et al., 2013). In contrast, hastening the development of astrocyte reactivity by knocking out suppressor of cytokine signaling 3 (SOCS3; the negative feedback molecule of STAT3) improved compaction of the lesion site and functional recovery (Okada et al., 2006). A recent study by Wong et al. (2015) subjected rats to transient OHT. In common with our results and the studies in the CNS just mentioned, they found that STAT3 was activated early after injury and that inhibiting its activation reduced astrocyte reactivity; however, this inhibition was associated with an improved ganglion cell survival, although the improvement was marginal. Furthermore, cell counts were performed only on hematoxylin and eosin–stained material and included all cells in the ganglion cell layer, of which 59% are not ganglion cells but are displaced amacrine cells (Jeon et al., 1998). Our results here are consistent with the findings in the brain and spinal cord: that reactivity is beneficial and, if prevented, results in a greater ganglion cell and functional loss.

Axon–astrocyte relationship within the optic nerve head
What is the communication between the axons and astrocytes in the lamina region? Are the axons injured first, which in turn send extracellular distress signals to the astrocytes instructing them to become reactive, do the astrocytes respond first and then affect the axons, or do both occur simultaneously? In the first case, an increase in IOP could cause a subthreshold insult to the axons (Quigley, 1999; Buckingham et al., 2008). Although axons are capable of sustaining minor membrane deformations, they are relatively rigid structures within an elastic extracellular support (Javid et al., 2014), and deleterious mechanical stress experienced by IOP rises could induce plasmalemmal instability and cytoskeletal disassembly (Pettus and Povlishock, 1996; Singleton and Povlishock, 2004). ATP has been suggested as one such signaling molecule (Ahmed et al., 2000; Verderio and Matteoli, 2001; Neary et al., 2003, 2005); it can be released from axons of the white matter (Fields and Stevens, 2000; Hamilton et al., 2008; Fields and Ni, 2010). In the second case, astrocytes could respond directly to the pressure by membrane stretching or distortions. Astrocytes, including those in the optic nerve head, express mechanosensitive ion channels as well as nontraditional, stretch-sensitive cation channels (Bowman et al., 1992; Islas...
et al., 1993; Choi et al., 2015). Such stretch injury can lead to the secretion of ATP or vasoactive molecules such as endothelin-1 and isoprostanes, as well as inositol triphosphate and matrix metalloproteinase 9 (Bzigelinski et al., 1997; Hoffman et al., 2000; Ostrow et al., 2011; Ralay Ranaivo et al., 2011; Pan et al., 2012). These diverse effects could have a wide variety of consequences that impact neighboring astrocytes and axons. For example, ATP is known to induce a rapid rise in [Ca²⁺] in reactive astrocyte networks, which precede polarization of the astrocyte processes toward the site of injury and recruitment of microglia and neutrophils (Davalos et al., 2005; Kim and Dustin, 2006; Roth et al., 2014).

Does up-regulation of STAT3 and the associated reactivity suggest a path toward a glaucoma therapy? Long-term constitutive activation of STAT3 (e.g., the phosphorylation of STAT3) is abnormal and highly oncogenic; the STAT3 pathway contributes to tumor cell proliferation and survival and maintaining an inflammatory environment (Yu and Jove, 2004; Wang et al., 2012a). However, in vivo and in vitro activation of STAT3 by the pharmacological agent colchicine resulted in a neuroprotective effect against Alzheimer’s disease and amyotrophic lateral sclerosis-related toxicity, with no reported effects of inflammation or glioma development (Chiba et al., 2005; Matsuoka et al., 2006; Wu et al., 2015). An important first step might be determining a potential short-term therapeutic window, i.e., an appropriate time and duration for STAT3 activation.

MATERIALS AND METHODS

Animals

All experiments with animals were approved by the Institutional Animal Care and Use Committee of Massachusetts Eye and Ear Infirmary. Male mice age 2–3 mo were housed in a 12-h light/dark cycle and received food and water ad libitum. Three mouse strains were used in this study: (1) wild-type C57BL/6 (stock no. 000664; The Jackson Laboratory), (2) an astrocyte-specific STAT3 CKO strain, referred to as GFAP-STAT3-CKO, and (3) mice homozygous for STAT3-loxP but without the GFAP-Cre transgene, referred to as GFAP-STAT3-Cre+. This third strain served as a control to the GFAP-STAT3-CKO strain of mice. Both the STAT3-loxP and GFAP-Cre mice are on C57BL/6 backgrounds, and so we have included these mice in this study.

To generate the STAT3 CKO line (GFAP-STAT3-CKO), mice heterozygous for GFAP-Cre (B6.Cg-Tg[GFAP-cre]73.12Mvs/J; stock no. 012886; The Jackson Laboratory) were crossed to mice homozygous for STAT3-loxP, which has exon 22 of the STAT3 gene flanked by loxP sites (Takeda et al., 1998; Herrmann et al., 2008). Exon 22 is a region necessary for STAT3 activation. M. Sofroniew (University of California, Los Angeles, Los Angeles, CA) provided the STAT3-loxP mice. GFAP-STAT3-CKO mice developed and thrived in a manner indistinguishable from their control strain and C57BL/6 mice. They appeared normal in size and did not display any gross physical or behavioral abnormalities. Astrocytes in the white and gray matter were similar in size, shape, overall appearance, and density in both control and the STAT3 KO mice (Herrmann et al., 2008). We also found that there was no difference in the general cytoarchitecture of the optic nerve and retina and the appearance of the astrocytes between the control and STAT3 KO mice. To test the specificity of Cre targeting to astrocytes in the retina and optic nerve, GFAP-Cre mice were crossed to a reporter strain that expressed tdTomato downstream from loxP-flanked stop signals via the ROSA promoter (B6;129S4-Socs3tm1Ayos/J; stock no. 023035; The Jackson Laboratory). In the offspring, tdTomato colocalized with established astrocyte-specific markers GFAP, S100β, and vimentin (Fig. S3).

Tissue preparation

Animals were anesthetized with an intraperitoneal injection of 100 mg/ml ketamine and 20 mg/ml xylazine and, when required, euthanized by carbon dioxide overdose. The skull was opened, and the brain was carefully removed to expose the optic nerve and chiasm. The head of the animal was fixed in 4% paraformaldehyde for 4 h at 4°C and then rinsed in PBS (3 × 5 min). Procedures for dissecting the optic nerve and retina have been previously described (Sun et al., 2009, 2010). The optic nerve was cryoprotected overnight in 30% sucrose at 4°C, mounted in freezing medium, and sectioned at 14-μm thickness. Sections were collected on coated slides and either stored at −20°C or used immediately. Retinas were stored in PBS at 4°C until needed.

Immunohistochemistry

Optic nerve sections or whole retinas were washed in PBS (3 × 5 min) and then incubated in blocking solution (5% donkey serum, 0.5% Triton X-100, and 1% bovine serum albumin in PBS) for 1 h at room temperature (RT), followed by incubation in primary antibodies either overnight (optic nerves) or for 3–5 d (retinas), always at 4°C. The primary antibodies used were: rabbit anti-GFAP (1:2,000; Abcam), mouse anti-SMI32 (1:400; Covance), rabbit anti–S100β (1:200; Abcam), mouse anti–vimentin (1:100; Abcam), rabbit anti–βIII-tubulin (1:200; Cell Signaling Technology), mouse anti–GFAP (1:400; Sigma-Aldrich), mouse anti–pSTAT3 (1:100; Cell Signaling Technology), and mouse anti–STAT3 (1:2,000; Cell Signaling Technology). The next day, tissue were washed in PBS (3 × 5 min) and incubated with secondary antibodies conjugated to rhodamine (1:200; donkey anti–rabbit; Jackson ImmunoResearch Laboratories, Inc.) or FITC (1:400; donkey anti–mouse; Jackson ImmunoResearch Laboratories, Inc.) for 2 h (optic nerves) or 3 d (retinas) at RT. Optic nerve sections were washed in PBS (3 × 5 min) and mounted in ProLong Gold Antifade medium (Thermo Fisher Scientific). Retinas were incubated with the nuclear dye DAPI for 20 min, washed in PBS (3 × 5 min), and mounted in Vectashield (Vector Laboratories).

Image collection and analysis

Images were acquired on a laser scanning confocal microscope (TCS SP5; Leica Biosystems) and then exported into ImageJ.
Axon loss was determined from PPD-stained optic nerve cross sections. Six rectangular regions from each section were photographed at a magnification of 100 (87 × 65 μm²). Axons were counted using the threshold and analyze particles functions of Image J. Damaged axons stain darkly with PPD and are not counted. Using this automated method, we found that the number of axons counted was within 7% of the number determined manually by four independent observers blind to the genotype of the animal and the experimental condition. Axonal densities per optic nerve were calculated by averaging the data from the six regions. The percentage of axon loss was calculated as the number of axons in the treated eye divided by the number in the untreated eye. The area of the optic nerve cross section was determined three times by outlining its outer border using Image J and then averaged. Axon counts were performed by individuals blinded to the genotype of the animals and the injury induced.

**Transient OHT**

Using a micromanipulator, the tip of a glass microneedle (50 μm) is inserted into the anterior chamber through the center of the cornea. The needle is connected to a pressure transducer, which is in series with a sterile saline bag, the height of which determines the hydrostatic pressure delivered to the eye (John et al., 1997; Kong et al., 2009; Sun et al., 2013; Crowston et al., 2015). Pressure transducer calibration was performed by referencing to a sphygmomanometer. Based on the normal mouse IOP, our previous results, and the levels to which IOP is typically elevated in other experimental models (increased to 23–30 mmHg, including in a model of hereditary glaucoma), the IOP was raised to 30 mmHg for 2 h (John et al., 1998; Libby et al., 2005; Saleh et al., 2007; Kong et al., 2009; Sun et al., 2013). This level of IOP elevation does not cause ischemia (Sun et al., 2013).

**Chronic OHT**

Chronic OHT was induced using the microbead occlusion model. A glass microneedle was inserted into a corneal puncture initially created by a 30.5-gauge needle, and 2–3 μl of 15-μm–diameter polystyrene microbeads (no. F8841; Thermo Fisher Scientific) was injected (final concentration of 2.7 × 10⁷ beads/ml suspended in PBS). The microbeads are inert and have been used in numerous studies of experimental glaucoma (Sappington et al., 2010; Chen et al., 2011; Della Santina et al., 2013; Gao and Jakobs, 2016). This method induces an elevation in IOP that lasts 4 wk and reaches a peak of 22–27 mmHg at 4–6 d after injection. In all cases, the untreated left eye showed no increase in IOP. A separate group of mice received a saline injection in lieu of the microbeads, and they exhibited normal levels of IOP over the 30-d experimental period (Fig. S2 C; n = 6 per group; mean IOP over the 30 d: C57BL/6, 10.3 ± 1.1 mmHg; GFAP–STAT3-Cre, 9.3 ± 1 mmHg; and GFAP–STAT3–CKO, 10.1 ± 1.2 mmHg). Mice were regularly examined on a slit lamp for signs of axon loss with PPD stain

Optic nerves were fixed with half-strength Karnovsky’s fixative (2% formaldehyde/2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer, pH 7.4; Electron Microscopy Sciences) for a minimum of 12 h at 4°C. Then, tissue was rinsed in 0.1 M sodium cacodylate buffer, postfixed with 2% osmium tetroxide in 0.1 M sodium cacodylate buffer, and en bloc stained with 2% aqueous uranyl acetate. Then, the tissue was dehydrated with graded ethyl alcohol solutions, transitioned with propylene oxide, resin infiltrated in tEPON-812 epoxy resin (Tousimis), and polymerized in silicone molds at 60°C. Ultrathin sections were cut at 70–90-nm thickness from the epoxy block using an EM UC7 ultramicrotome (Leica Biosystems) and a diamond knife and then collected onto grids stained with 2% aqueous uranyl acetate and Sato’s Lead citrate. Grids were imaged using a transmission electron microscope (Tecnai G2 Spirit; Thermo Fisher Scientific) at 80 kV interfaced with a digital charge-coupled device camera (AMT XR41; Advanced Microscopy Techniques) for digital TIFF file image acquisition.

PPD differentially stains damaged axons, allowing for sensitive detection of axon injury (Howell et al., 2007; Gao and Jakobs, 2016). Semi-thin sections were cut at 1 μm with a diamond knife on the UC7 ultramicrotome, collected on slides, and then dried on a slide warmer. Slides were stained with 2% aqueous PPD solution (MP Biomedicals) for 30 min at RT, rinsed, air dried, and then mounted and cover-slipped.
of any inflammatory response or overt damage in the anterior segment. Mice that showed any of these signs were excluded.

To determine whether each animal received the same degree of insult from the elevation in IOP, we calculated the area under the IOP-versus–days after injury curve (Fig. S2 D; Gao and Jakobs, 2016) using Excel (Microsoft). This area was referred to as the cIOP and gives a measure of the total pressure insult the eye was subjected to during the 30-d experimental period. Then, we measured the ΔcIOP for each animal as the cIOP of the treated eye minus the cIOP of the contralateral untreated eye (Gao and Jakobs, 2016). There was no significant difference in the ΔcIOP or peak IOP between any of the strains (Fig. S2 D).

Optic nerve crush
After anesthesia and topical corneal analgesic of mice, the optic nerve of one eye was exposed and clamped ~0.2 mm from the globe within the myelinated portion of the nerve (Fig. S3 E). The clamp was performed for 10 s using a self-closing jeweler’s forceps (FST self-closing forceps, curved tip; Sun et al., 2010).

Measuring IOP
Mice were anaesthetized by isoflurane (2–4%; Webster Veterinary) delivered in 100% oxygen via a precision vaporizer. Measurements were taken 4–5 min after animals lost consciousness, which was defined as failure to detect motion in response to forced movement and absence of eye blinking. The IOPs were measured in both eyes 1 d before microbead injection and then every 3 d afterward using a tonometer (TONOLAB; Icare). Measurements of IOP using the tonometer match well with manometrically measured IOPs, validating this technique as precise and reproducible (Wang et al., 2005; Prusky et al., 2006; Della Santina et al., 2013; Gao and Jakobs, 2016). Measurements were made at the same time in the morning. The tonometer takes five measurements and, based on this, gives a single mean. We considered this as one measurement; five measurements were made from each eye, and the mean was calculated to represent the IOP. IOPs were measured by individuals blinded to the genotype of the animal and the injury induced.

Retinal ganglion cell counts
Images of the whole mounted retina were obtained as z stacks (0.35-µm step size) at a magnification of 40. Each retina was divided into quadrants, and two midperipheral regions were imaged per quadrant, for a total of eight images per retina. All cells that colocalized βIII-tubulin, a ganglion cell–specific marker (Chen et al., 2011; Gao and Jakobs, 2016), and the nuclear dye DAPI were counted, and from the mean of the eight images, a ganglion cell density per retina was obtained. Percent ganglion cell loss was determined by comparing the ganglion cell density of the treated eye to the untreated contralateral eye. Cell counts were performed by individuals blinded to the genotype of the animal and the injury induced.

ERG
Full-field ERGs were recorded simultaneously from both eyes using a ColorDome system (Diagnosys LLC). Animals were dark adapted overnight (>14 h) and anesthetized, and their pupils were dilated with 1% tropicamide. Corneal anesthesia was achieved with a drop of proparacaine hydrochloride (0.5%; Akorn Inc.). Signals were recorded using gold wire loop electrodes (Diagnosys LLC). Active electrodes were precoated with GenTeal gel drops (Alcon) and placed on the center of each cornea. A reference electrode was inserted in the mouth, and a ground electrode was inserted into the tail. Animal and electrode placements were all performed under dim red light (<640 nm), which maintained dark adaptation. A heating pad was used to maintain body temperature at 37°C.

Scotopic responses were obtained for flash intensities ranging from −3.16 log cd.s.m⁻² to 2.13 log cd.s.m⁻² in 1-log unit increments, by averaging 2–20 responses per intensity (20 for the dimmest and 2 for the brightest), with a progressively lengthened interstimulus interval of 5–60 s. This allowed for complete recovery of the b-wave amplitude. STRs were obtained for flash intensities from −5.5 log cd.s.m⁻² to −3 log cd.s.m⁻² by averaging 50–60 responses per intensity, with an interstimulus interval of 2 s.

For scotopic response analysis, the a-wave amplitude was measured from the baseline to the trough of the first negative wave, and the b-wave amplitude was measured from the trough of the a-wave to the peak of the first positive wave (peak-to-peak amplitude). For STR analysis, pSTR amplitude was measured from baseline to the first positive peak. ERGs were recorded before and after injury, and responses after injury were normalized to preinjury values for the same eye. ERGs were recorded by individuals blinded to the genotype of the animal and the injury induced.

Optomotor response
Visual acuity of mice was measured using an optomotor reflex-based spatial frequency threshold test (Douglas et al., 2005; Prusky et al., 2006; Della Santina et al., 2013; Gao and Jakobs, 2016). Freely moving mice were placed on a pedestal located in the center of an arena formed by four computer monitors arranged in a quadrangle. The monitors displayed a moving vertical black and white sinusoidal grating pattern. An observer, unable to see the direction of the bars, determined the direction of bar rotation by monitoring the tracking behavior of the mouse. Tracking was considered positive when there was a reproducible smooth pursuit of the head or rotation of the body in the direction concordant with the stimulus. Each eye could be tested separately depending on the direction of rotation of the grating. The staircase method was used to determine the spatial frequency at which the animal no longer responded. Rotation speed (12°/s) and contrast (100%) were kept constant. Responses were measured before and after injury by individuals blinded to the genotype of the animal and the injury induced.
Statistical analysis
For Fig. 4 (B and L) and Fig. 5, one-way ANOVA with Tukey’s posttest was performed. For Figs. 7, 8, and 9, comparisons among the three mouse strains over time were done using two-way repeated-measures ANOVA with Bonferroni correction for three selected comparisons (GFAP–STAT3–C KO vs. GFAP–STAT3–Cre⁺, GFAP–STAT3–C KO vs. C57BL/6, and GFAP–STAT3–Cre⁺ vs. C57BL/6). For these figures, we have focused on whether there is a significant difference between the GFAP–STAT3–C KO and its control strain (GFAP–STAT3–Cre⁺). A p-value <0.05 was considered significant. Note that we are not comparing results across injury models but between mouse strains within each injury model. Statistical analysis was performed on the absolute numbers using Prism (v5.0; GraphPad Software).

Online supplemental material
Table S1 shows the absolute numbers for the amount of GFAP immunonegative space and process hypertrophy after astrocyte remodeling within the glial lamina. Table S2 shows the absolute numbers for the counts of ganglion cell soma and axons. Fig. S1 shows that the IOPs, ganglion cell numbers, spatial frequency threshold, and ERG of GFAP–STAT3–C KO mice are similar to their control strain and C57BL/6 mice. Fig. S2 shows that, when injected with microbeads, GFAP–STAT3–C KO and GFAP–STAT3–Cre⁺ mice undergo IOP elevation in a similar pattern to C57BL/6 mice. Fig. S3 shows that, within the optic nerve head, Cre expression was localized to astrocytes. It also shows where along the optic nerve the crush was performed.

ACKNOWLEDGMENTS
We thank Richard Masland for critical comments on this manuscript. We would also like to thank Oscar Morales for his support with the ERG and optomotor response experiments and Philip Seifert from the Histology Core Facility for assistance with the electron microscope.

This work was supported by the National Institutes of Health (grants R01 EY022032 and R01 EY019703 and core grant P30 EY003790), Research to Prevent Blindness, and the donors of National Glaucoma Research, a program of the BrightFocus Foundation.

The authors declare no competing financial interests.


Astrocyte reactivity protects function in glaucoma | Sun et al.


Astrocyte reactivity protects function in glaucoma

Sun et al. 2011.11.062


